TMO

Thermo Fisher Scientific Inc.

$446.03

-2.89%
May 13, 2026
Bobby Quantitative Model
Thermo Fisher Scientific Inc. is a global leader in providing scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents, operating within the Medical Diagnostics & Research industry. The company is a dominant market leader and consolidator, distinguished by its comprehensive, end-to-end product and service portfolio across four key segments: Analytical Technologies, Specialty Diagnostic Products, Life Science Solutions, and Lab Products & Services, which includes contract research organization (CRO) capabilities. The current investor narrative is focused on the company's ability to demonstrate operational resilience and deliver strong core growth following the post-pandemic normalization, as evidenced by recent quarterly results and raised long-term guidance, while simultaneously navigating emerging challenges such as renewed inflationary pressures and geopolitical tensions.

People also watch

Danaher Corporation

Danaher Corporation

DHR

Analysis
IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

IDXX

Analysis
Agilent Technologies

Agilent Technologies

A

Analysis
Waters Corporation

Waters Corporation

WAT

Analysis
Natera

Natera

NTRA

Analysis

TMO 12-Month Price Forecast

Historical Price
Current Price $446.03
Average Target $446.03
High Target $512.9345
Low Target $379.1255

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $579.84 and implied upside of +30.0% versus the current price.

Average Target

$579.84

13 analysts

Implied Upside

+30.0%

vs. current price

Analyst Count

13

covering this stock

Price Range

$357 - $580

Analyst target range

Buy
3 (23%)
Hold
6 (46%)
Sell
4 (31%)

Thermo Fisher is covered by 13 analysts, indicating strong institutional interest. The consensus sentiment is bullish, with recent institutional ratings showing a preponderance of 'Buy' or 'Overweight' actions, including upgrades from Citigroup and Keybanc in December 2025. The average target price is derived from estimated EPS and revenue figures, with the consensus EPS estimate for the forward period at $38.87 on revenue of $58.23 billion. The full target range, implied by the EPS estimates, spans from a low of $37.94 to a high of $39.36. The high-end target assumes successful execution on growth initiatives, margin preservation, and perhaps multiple expansion, while the low-end target likely factors in risks such as persistent inflation, competitive pressures, or slower-than-expected end-market demand. The relatively tight spread between the low and high EPS estimates signals strong analyst conviction in the company's near-term earnings trajectory, though the recent stock price decline indicates the market is currently more focused on the associated risks than the consensus optimism.

Drowning in data?

Find the real signal!

Bulls vs Bears: TMO Investment Factors

The evidence presents a classic battle between strong fundamentals and weak technicals. The bull case is anchored in Thermo Fisher's robust profitability, cash generation, and a forward valuation that prices in a meaningful earnings recovery, supported by a bullish analyst community. The bear case is driven by a severe price downtrend, decelerating growth narrative, and vulnerability to macro headwinds. Currently, the bearish technical momentum and market sentiment appear to have the upper hand, overshadowing the solid underlying business performance. The single most important tension in the investment debate is whether the company's forward earnings growth of approximately $38.87 per share (implied by the forward P/E) is achievable, or if inflationary pressures and a post-pandemic normalization will lead to further earnings disappointments and multiple compression.

Bullish

  • Strong Forward Earnings Growth: The forward P/E of 17.17x is nearly half the trailing P/E of 32.34x, indicating the market expects a significant earnings recovery. Analyst consensus projects forward EPS of $38.87, implying strong growth from the Q4 2025 EPS of $5.22.
  • Robust Profitability and Cash Flow: The company maintains high profitability with a Q4 net margin of 16.17% and a TTM operating margin of 18.20%. It generates substantial free cash flow, with TTM FCF of $6.29 billion, providing ample liquidity for growth and shareholder returns.
  • Recurring Revenue Model Stability: The business model is resilient, with Consumables ($5.03B) and Service ($4.97B) comprising the bulk of Q4 revenue. This recurring revenue base provides stability, evidenced by steady sequential quarterly revenue growth from $10.36B to $12.22B in 2025.
  • Valuation Near Historical Lows: The trailing P/E of 32.34x sits below the stock's own historical range, where it has frequently traded above 35x. This positions the stock at the lower end of its historical valuation band, suggesting a potential value opportunity if growth meets expectations.

Bearish

  • Severe Technical Downtrend: The stock is in a pronounced downtrend, down 18.91% over 3 months and 17.30% over 6 months. It has significantly underperformed the market, with a -15.10% relative strength over the past month, indicating strong negative momentum.
  • Revenue Growth Deceleration: While Q4 revenue grew 7.2% YoY, this represents a deceleration from the pandemic-inflated growth rates. The stock's recent sharp decline suggests the market is pricing in concerns over a slower growth trajectory in a normalized environment.
  • Elevated Valuation vs. Peers: Despite the recent sell-off, the forward P/E of 17.17x and P/S of 4.89x remain at a premium to many industrial and healthcare equipment peers. This leaves the stock vulnerable to valuation compression if growth disappoints.
  • Macro and Inflationary Headwinds: Recent news highlights the company flagging 'modest inflation' risk amid geopolitical tensions. Persistent cost pressures could threaten the stable gross margin of 37.95% and operating margin of 18.85% achieved in Q4.

TMO Technical Analysis

The prevailing price trend is a pronounced downtrend from recent highs, with the stock down 18.91% over the past three months and 17.30% over the past six months. Currently trading at $469.21, the price sits approximately 72.8% of its 52-week range ($385.46 to $643.99), positioning it closer to the lower bound, which suggests a potential value opportunity but also reflects significant negative momentum and investor concern. Recent short-term momentum is decisively negative and diverges sharply from the broader market, with the stock down 5.12% over the past month against a 9.98% gain for the SPY, resulting in a severe relative strength reading of -15.10; this underperformance indicates company-specific or sector-specific headwinds are overwhelming any positive market sentiment. Key technical support is anchored at the 52-week low of $385.46, while immediate resistance lies near the recent breakdown level around $500-$520, with major resistance at the 52-week high of $643.99. A sustained breakdown below the $385 support would signal a continuation of the bearish trend and potentially trigger further selling, whereas a recovery above the $520 resistance could indicate the downtrend is stabilizing. The stock's beta of 0.972 indicates its volatility is nearly in line with the broader market, but the recent price action, including a maximum drawdown of -27.38%, highlights that it has experienced significant idiosyncratic risk and downside pressure independent of market movements.

Beta

0.88

0.88x market volatility

Max Drawdown

-30.3%

Largest decline past year

52-Week Range

$385-$644

Price range past year

Annual Return

+4.0%

Cumulative gain past year

PeriodTMO ReturnS&P 500
1m-13.3%+8.2%
3m-12.5%+9.0%
6m-22.9%+10.5%
1y+4.0%+26.5%
ytd-24.7%+8.9%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

TMO Fundamental Analysis

Revenue growth remains positive but has decelerated from prior pandemic-inflated levels; the most recent Q4 2025 revenue was $12.22 billion, representing a 7.2% year-over-year growth, which is a healthy organic rate for a company of this scale. Sequentially, revenue has grown from $10.36B in Q1 to $12.22B in Q4, indicating steady quarterly progression, with segment data showing the Consumables ($5.03B) and Service ($4.97B) lines as the largest contributors, underscoring the stability of its recurring revenue model. The company is highly profitable, with Q4 2025 net income of $1.98 billion and a net margin of 16.17%. Gross margin for the quarter was 37.95%, which is consistent with the trailing twelve-month gross margin of 37.66%, indicating stable pricing power and cost management. Operating margin was 18.85% for the quarter, aligning closely with the TTM operating margin of 18.20%, demonstrating disciplined operational execution despite inflationary pressures noted in recent news. Balance sheet health is robust, supported by strong cash generation; the company reported free cash flow of $2.99 billion for Q4 2025 and TTM free cash flow of $6.29 billion, providing ample internal funding for growth initiatives and shareholder returns. The debt-to-equity ratio of 0.76 is manageable for the industry, and the current ratio of 1.89 indicates solid short-term liquidity. Return on equity of 12.61% reflects efficient use of shareholder capital, though it has moderated from peak levels.

Quarterly Revenue

$12.2B

2025-12

Revenue YoY Growth

+0.07%

YoY Comparison

Gross Margin

+0.37%

Latest Quarter

Free Cash Flow

$6.3B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Consumables
Instruments
Service

Open an Account, get $2 TSLA now!

Valuation Analysis: Is TMO Overvalued?

Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 32.34x, while the forward PE is significantly lower at 17.17x, indicating the market expects a substantial recovery in earnings over the next twelve months, with forward estimates implying an EPS of approximately $38.87. Compared to sector averages, Thermo Fisher trades at a premium. Its forward PE of 17.17x is above the typical healthcare equipment & supplies industry average (often in the low-to-mid 20s for forward PE), but the discount to its own trailing multiple suggests the market has already priced in a near-term earnings contraction. The Price-to-Sales ratio of 4.89x and EV/Sales of 4.83x are also elevated relative to many industrial peers, justified by the company's superior margins, market leadership, and resilient business model. Historically, the current trailing PE of 32.34x sits below the stock's own historical range seen in recent years, where it has frequently traded above 35x and even into the 40s during peak growth phases. This positioning near the lower end of its historical valuation band suggests the market is pricing in more conservative growth expectations, potentially creating a value opportunity if the company can meet or exceed its forward earnings guidance and demonstrate sustained margin stability.

PE

32.3x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 19x~43x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

21.7x

Enterprise Value Multiple

Investment Risk Disclosure

Financial & Operational Risks: Thermo Fisher's primary financial risk is not leverage or liquidity—its debt-to-equity of 0.76 and current ratio of 1.89 are manageable—but rather margin pressure. The company has flagged 'modest inflation' as a risk, which could threaten its stable Q4 gross margin of 37.95% and operating margin of 18.85%. While revenue growth remains positive at 7.2% YoY, the deceleration from higher pandemic-era levels introduces earnings volatility risk, especially as the stock's valuation (forward P/E 17.17x) still implies healthy growth. Dependence on this growth to justify its premium multiples is a key financial vulnerability.

Market & Competitive Risks: The stock trades at a premium to sector averages (forward P/E 17.17x vs. often lower industry peers), creating valuation compression risk if growth disappoints. Its beta of 0.972 indicates market-correlated volatility, but the severe -27.38% maximum drawdown and -15.10% monthly relative strength show it is facing intense company/sector-specific selling pressure independent of the broader market rally. This suggests risks related to sector rotation out of life sciences tools post-pandemic and potential competitive pressures on pricing in a normalized demand environment.

Worst-Case Scenario: The worst-case scenario involves a combination of persistent inflation eroding margins, a deeper-than-expected slowdown in biopharma capital spending, and a failure to meet the forward EPS target of ~$38.87. This could trigger multiple compression towards the sector's lower end and a re-test of the 52-week low. The chain of events would likely start with a guidance cut or an earnings miss, leading to analyst downgrades and sustained outflows. Realistic downside from the current price of $469.21 is approximately -17.8% to the 52-week low of $385.46, with the potential for further declines if the $385 support level fails.